Goldman Sachs Group Inc. Buys Shares of 88,463 Genelux Corporation $GNLX

Goldman Sachs Group Inc. bought a new position in shares of Genelux Corporation (NASDAQ:GNLX) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 88,463 shares of the company’s stock, valued at approximately $239,000. Goldman Sachs Group Inc. owned about 0.23% of Genelux as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the company. Advisor Resource Council bought a new stake in Genelux during the 1st quarter worth $34,000. Liberty Wealth Management LLC acquired a new stake in shares of Genelux during the first quarter valued at about $45,000. 5T Wealth LLC bought a new stake in shares of Genelux during the first quarter worth about $49,000. American Century Companies Inc. acquired a new position in shares of Genelux in the first quarter valued at approximately $51,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in shares of Genelux in the first quarter valued at approximately $68,000. 37.33% of the stock is currently owned by institutional investors.

Genelux Stock Down 0.2%

GNLX stock opened at $4.20 on Monday. The firm has a market cap of $158.63 million, a price-to-earnings ratio of -4.88 and a beta of -0.32. The company’s fifty day simple moving average is $3.61 and its 200 day simple moving average is $3.10. Genelux Corporation has a 12-month low of $1.99 and a 12-month high of $5.89.

Genelux (NASDAQ:GNLX) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.20) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.02. Research analysts expect that Genelux Corporation will post -0.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on GNLX shares. HC Wainwright reissued a “buy” rating on shares of Genelux in a report on Wednesday, July 23rd. Wall Street Zen upgraded shares of Genelux from a “sell” rating to a “hold” rating in a report on Saturday, July 12th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $20.33.

Genelux Company Profile

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.